figuring out the actual risk of COX-2 inhibitors
March 2005
Health Canada is getting closer to figuring out the actual risk of COX-2 inhibitors...and how to use them appropriately.
They will be adding new special warnings and dosage limits to the COX-2 inhibitors remaining on the market.
Vioxx might even come back in some countries. That's because now we know cardiovascular problems aren't unique to Vioxx...and it's the ONLY COX-2 so far that has proven GI benefits.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter Canada includes:
- 12 issues every year, with brief articles about new meds and hot topics
- 200+ CE courses, including the popular CE-in-the-Letter
- Quick reference drug comparison charts
- Access to the entire archive